November 23rd 2024
FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.
November 22nd 2024
November 21st 2024
SGS Opens New Clinical Research Site in Belgium and Expands Biosafety Testing Capacity in UK
October 28th 2021SGS’s new Antwerp, Belgium, clinical research site will house both clinical trial patients and good manufacturing practice drug manufacturing, and its Glasgow, UK, biosafety testing site now has increased testing capacity.
MilliporeSigma Completes $110-Million Contract Development Manufacturing Facility for Gene Therapy
October 15th 2021MilliporeSigma announced the opening of its second Carlsbad, California-based facility, which doubles production capacity to support commercial and industrial manufacturing of viral vectors.